Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by loki69on Apr 16, 2010 7:45pm
554 Views
Post# 17002154

RE: my useless 2 cents on the warrants

RE: my useless 2 cents on the warrants

Basically, the warrants give the holder of the bought deal at .35 the right to exchange 1/2 warrant at an excise price of .25, but the deal is for 1 FULL warrant at .50. The extension is positive to the share holders and warrant holder as the company has said in a round about way, the results are coming and they will be positive. Instead of letting the warrants expire BEFORE the news release of the Phase IIB , they have extended the deadline because they believe the stock will be higher than .50. This way the company makes extra funds, and capital to run the advancement of the trials.
I do not know who holds the warrants, but the company is definately giving them extra time to decide to excise when the Phase IIB data is released. This is one hell of a deal for the warrant holders. I honestly see the stock at or above .50 when the results are released and as soon as the market absorbes the extra shares, the stock will proceed up. It could explode also on a partnership deal and blow by .50 very quick.

May will be very interesting!

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse